USD10
ANRO Anteile
Über Alto NeuroscienceAlto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
USD10
ANRO Anteile
Über Alto NeuroscienceAlto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Statistiken
TRADINGFENSTER
Geschlossen
ÖFFNET AM
Nicht genügend Daten
MARKTKAPITALISIERUNG
666,99 Mio. $
ERÖFFNUNGSPREIS
21,25 $
TIEF (1 J)
1,60 $
HOCH (1 J)
25,17 $
TIEF (24 STD.)
20,57 $
HOCH (24 STD.)
22,40 $
VOLUMEN (24 STD.)
423.679,17 $
21,93 %
Kursverlauf
Time | Price | Change |
|---|---|---|
Heute | 21,25 $ | |
1 Tag | 21,00 $ |